JPS5896026A - 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 - Google Patents

新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤

Info

Publication number
JPS5896026A
JPS5896026A JP56172908A JP17290881A JPS5896026A JP S5896026 A JPS5896026 A JP S5896026A JP 56172908 A JP56172908 A JP 56172908A JP 17290881 A JP17290881 A JP 17290881A JP S5896026 A JPS5896026 A JP S5896026A
Authority
JP
Japan
Prior art keywords
urokinase
group
derivative
polyethylene glycol
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56172908A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0525470B2 (enExample
Inventor
Kimihiro Shimizu
清水　公博
Tsuguji Nakahara
中原　嗣二
Taketoshi Kinoshita
木下　猛敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Priority to JP56172908A priority Critical patent/JPS5896026A/ja
Priority to ES516680A priority patent/ES516680A0/es
Priority to BR8206347A priority patent/BR8206347A/pt
Priority to US06/437,009 priority patent/US4495285A/en
Priority to CH6304/82A priority patent/CH658669A5/fr
Priority to DE19823240174 priority patent/DE3240174A1/de
Priority to SE8206173A priority patent/SE457800B/sv
Priority to FR8218223A priority patent/FR2515684B1/fr
Priority to IT68274/82A priority patent/IT1191221B/it
Priority to CA000414556A priority patent/CA1203764A/en
Priority to GB08230987A priority patent/GB2110219B/en
Publication of JPS5896026A publication Critical patent/JPS5896026A/ja
Priority to US06/546,590 priority patent/US4640835A/en
Priority to CA000443230A priority patent/CA1217718A/en
Priority claimed from CA000443230A external-priority patent/CA1217718A/en
Publication of JPH0525470B2 publication Critical patent/JPH0525470B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP56172908A 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 Granted JPS5896026A (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP56172908A JPS5896026A (ja) 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
ES516680A ES516680A0 (es) 1981-10-30 1982-10-20 Nuevos derivados de activadores plasminogenos
BR8206347A BR8206347A (pt) 1981-10-30 1982-10-27 Processo para produzir derivados ativadores de plasminogenio
US06/437,009 US4495285A (en) 1981-10-30 1982-10-27 Plasminogen activator derivatives
CH6304/82A CH658669A5 (fr) 1981-10-30 1982-10-28 Derives d'activateurs du plasminogene.
FR8218223A FR2515684B1 (fr) 1981-10-30 1982-10-29 Nouveau derive d'un activateur de plasminogene non immunogene d'origine humaine
SE8206173A SE457800B (sv) 1981-10-30 1982-10-29 Plasminogenaktivatorderivat
DE19823240174 DE3240174A1 (de) 1981-10-30 1982-10-29 Neue plasminogen-aktivatorderivate
IT68274/82A IT1191221B (it) 1981-10-30 1982-10-29 Derivati di attivatori di plasminogeno procedimento per la loro preparazione ed agente trombolitico comprendente tali derivati
CA000414556A CA1203764A (en) 1981-10-30 1982-10-29 Plasminogen activator derivatives
GB08230987A GB2110219B (en) 1981-10-30 1982-10-29 Plasminogen activator derivatives
US06/546,590 US4640835A (en) 1981-10-30 1983-10-28 Plasminogen activator derivatives
CA000443230A CA1217718A (en) 1981-10-30 1983-12-14 Plasminogen activator derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP56172908A JPS5896026A (ja) 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
CA000443230A CA1217718A (en) 1981-10-30 1983-12-14 Plasminogen activator derivatives

Publications (2)

Publication Number Publication Date
JPS5896026A true JPS5896026A (ja) 1983-06-07
JPH0525470B2 JPH0525470B2 (enExample) 1993-04-13

Family

ID=25670236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56172908A Granted JPS5896026A (ja) 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤

Country Status (9)

Country Link
US (1) US4495285A (enExample)
JP (1) JPS5896026A (enExample)
BR (1) BR8206347A (enExample)
CA (1) CA1203764A (enExample)
CH (1) CH658669A5 (enExample)
DE (1) DE3240174A1 (enExample)
FR (1) FR2515684B1 (enExample)
GB (1) GB2110219B (enExample)
SE (1) SE457800B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
JPS61155333A (ja) * 1984-11-30 1986-07-15 ビーチャム・グループ・ピーエルシー 新規化合物、その製法及びそれを含む医薬組成物

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4844897A (en) * 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0304311A1 (en) * 1987-08-21 1989-02-22 The Wellcome Foundation Limited Complex of polyethylene glycol and tissue plasminogen activator
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
IT1260468B (it) * 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1994001483A1 (en) * 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
CA2239775C (en) 1995-12-18 2008-07-15 Collagen Corporation Crosslinked polymer compositions and methods for their use
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
EP0922111B1 (en) * 1996-07-23 2004-12-01 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
AU1727500A (en) * 1998-11-17 2000-06-05 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US20020182172A1 (en) * 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1878441B1 (en) 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0213293A (pt) * 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP2184298A1 (en) * 2003-03-14 2010-05-12 Wyeth a Corporation of the State of Delaware Antibodies against human IL-21 receptor and uses therefor
ATE476448T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
WO2005044305A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
DK1682177T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi
NZ548785A (en) 2004-01-07 2011-08-26 Novartis Vaccines & Diagnostic M-CSF-Specific monoclonal antibody and uses thereof
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
CN104174071A (zh) 2004-04-28 2014-12-03 安希奥设备国际有限责任公司 用于形成交联生物材料的组合物和系统及关联的制备方法与用途
CA2581093C (en) 2004-09-17 2014-11-18 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
DK1827492T3 (da) 2004-11-30 2010-11-22 Curagen Corp Antistoffer rettet mod GPNMB og anvendelser deraf
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
EP1866338B1 (en) 2005-03-23 2016-09-21 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
ES2530265T3 (es) * 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
EP1913027B1 (en) * 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
EP2277916A3 (en) * 2005-07-28 2011-04-27 Novartis AG Use of antibody to M-CSF
JP5376574B2 (ja) 2005-12-15 2013-12-25 ゲンマブ エー／エス 自己免疫疾患の治療のためのエフェクター機能欠乏抗体の使用
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
EP2010569A4 (en) 2006-03-20 2009-09-09 Xoma Technology Ltd HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS
WO2007120787A2 (en) 2006-04-13 2007-10-25 Novartis Vaccines & Diagnostics, Inc. Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
NO346945B1 (no) 2006-06-30 2023-03-13 Novo Nordisk As Anti-NKG2A-antistoffer og anvendelser derav
EP2420252A1 (en) 2006-08-04 2012-02-22 Novartis AG EPHB3-specific antibody and uses thereof
AR064801A1 (es) * 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP2111412A2 (en) * 2007-02-02 2009-10-28 Amgen, Inc Hepcidin and hepcidin antibodies
JP2010521180A (ja) 2007-03-14 2010-06-24 ノバルティス アーゲー 癌を処置、診断または検出するためのａｐｃｄｄ１阻害剤
CA2708854C (en) 2007-12-14 2017-11-28 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
RU2010133892A (ru) 2008-01-24 2012-02-27 Ново Нордиск А/С (DK) Гуманизированные моноклональные антитела против человеческого nkg2a
JP5701064B2 (ja) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド フェロポーチン抗体およびその使用方法
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2724415C (en) 2008-05-15 2016-09-13 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
JP5422649B2 (ja) 2008-07-16 2014-02-19 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
CN102143974B (zh) 2008-07-16 2015-03-25 生命医学研究学会 人巨细胞病毒中和抗体及其用途
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US9340603B2 (en) * 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
JP5706821B2 (ja) * 2008-09-08 2015-04-22 オタワ ホスピタル リサーチ インスティテュート ペリオスチンに誘導される膵臓再生
BRPI0914012B1 (pt) 2008-10-13 2022-02-15 Institute For Research In Biomedicine Composição farmacêutica e uso da composição farmacêutica
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
TW201129379A (en) 2009-11-20 2011-09-01 Amgen Inc Anti-Orai1 antigen binding proteins and uses thereof
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
CN103153339B (zh) 2010-05-27 2021-05-04 根马布股份公司 针对her2表位的单克隆抗体
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
HRP20171789T1 (hr) 2010-06-15 2017-12-29 Genmab A/S Konjugati humanog protutijela s lijekom protiv tkivnog faktora
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
PL2654781T3 (pl) 2010-12-21 2018-09-28 Novartis Ag Przeciwciała anty-p-selektynowe i sposoby ich zastosowania i identyfikacji
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
LT2714735T (lt) 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
DK3418300T3 (da) 2011-07-18 2020-12-07 Inst Res Biomedicine Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf
AU2013237087B2 (en) 2012-03-20 2017-07-20 Humabs Biomed Sa Antibodies that neutralize RSV, MPV and PVM and uses thereof
EA201492262A1 (ru) 2012-06-06 2015-08-31 Бионор Иммуно Ас Конструкция пептидного каркаса
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
MX387324B (es) 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
HK1220466A1 (zh) 2013-03-14 2017-05-05 Regeneron Pharmaceuticals, Inc. 爱帕琳融合蛋白和其用途
AU2014236677B2 (en) 2013-03-15 2018-07-05 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
CN113667012B (zh) 2013-10-02 2024-07-12 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
WO2015109264A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
SG11201610777VA (en) 2014-07-11 2017-01-27 Genmab As Antibodies binding axl
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
WO2016013751A1 (ko) 2014-07-22 2016-01-28 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
JP6956630B2 (ja) 2014-07-24 2021-11-02 ジェネンテック， インコーポレイテッド 薬剤の少なくとも１つのトリスルフィド結合を含むタンパク質中のチオール部分へのコンジュゲーション方法
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
CN107106590B (zh) 2014-10-24 2022-10-18 阿斯利康(瑞典)有限公司 组合
CN107106669A (zh) 2014-11-04 2017-08-29 南加利福尼亚大学 用于治疗过度表达HIF‑1α的癌症的组合物和方法
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
CN107428819B (zh) 2014-11-18 2022-03-15 胡默波斯生物医学公司 强力地中和狂犬病毒和其它狂犬病毒属病毒的抗体和其用途
EP3916017A1 (en) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
ES2846748T3 (es) 2015-03-30 2021-07-29 Regeneron Pharma Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma
EP3292139B1 (en) 2015-05-05 2020-10-28 The Regents of The University of California H3.3 ctl peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3960761A1 (en) 2015-06-01 2022-03-02 MedImmune, LLC Neutralizing anti-influenza binding molecules and uses thereof
US20180179274A1 (en) 2015-06-26 2018-06-28 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
AU2016292762B2 (en) 2015-07-10 2022-07-28 Genmab A/S AXL-specific antibody-drug conjugates for cancer treatment
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
FI3334761T3 (fi) 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
US9884920B2 (en) 2015-10-09 2018-02-06 Florida State University Research Foundation, Inc. Antibodies specific for 4,6-diamino-5-(formamido)pyrimidine and uses thereof
AR108824A1 (es) 2015-11-21 2018-10-03 Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン，エルエルシー Ａ型インフルエンザを治療する方法
RU2760875C1 (ru) 2016-07-12 2021-12-01 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
EP3523330A1 (en) 2016-10-04 2019-08-14 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
JP7277363B2 (ja) 2016-11-01 2023-05-18 ジェンマブ ビー．ブイ． ポリペプチド変異体およびその使用
JP7217229B2 (ja) 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
EP4129321B1 (en) 2016-12-05 2025-10-15 Nuritas Limited Compositions comprising peptide wkdeagkplvk
EP3329905A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
US11325968B2 (en) 2016-12-16 2022-05-10 H. Lundbeck A/S Alpha-synuclein antibodies
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018127519A1 (en) 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
SG11201907260PA (en) 2017-02-06 2019-09-27 Lemonex Inc Physiologically active substance carrier
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
AU2018266847A1 (en) 2017-05-10 2019-11-28 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual HIV antiviral and immunomodulatory activity
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
US11530132B2 (en) 2017-09-05 2022-12-20 Lemonex Inc. Composition comprising porous silica particles carrying a cell fate modulating factor
EP3743440A1 (en) 2018-01-24 2020-12-02 Genmab B.V. Polypeptide variants and uses thereof
JP7525397B2 (ja) 2018-02-14 2024-07-30 ビエラ バイオ インコーポレイテッド ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
SG11202010388SA (en) 2018-04-30 2020-11-27 Takeda Pharmaceuticals Co Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
EP3820498A1 (en) 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide for disease treatment
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
DK3898668T5 (da) 2018-12-19 2024-08-05 Humabs Biomed Sa Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CA3131700A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
SG11202110626SA (en) 2019-03-27 2021-10-28 Umc Utrecht Holding Bv Engineered iga antibodies and methods of use
SG11202110610VA (en) 2019-04-09 2021-10-28 Abcuro Inc Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
US20220287347A1 (en) 2019-08-20 2022-09-15 Nuritas Limited Peptides for treating muscle atrophy
EP4021578A1 (en) 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
KR20220109391A (ko) 2019-10-22 2022-08-04 뉴리타스 리미티드 비-알콜성 지방간 질환의 치료
EP3862014A1 (en) 2020-02-07 2021-08-11 Nuritas Limited Treatment of panx1 associated diseases
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
KR20230016186A (ko) 2020-05-26 2023-02-01 트루바인딩 아이엔씨. 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
EP4171747A1 (en) 2020-06-24 2023-05-03 VIR Biotechnology, Inc. Engineered hepatitis b virus neutralizing antibodies and uses thereof
US20250277031A1 (en) 2021-01-08 2025-09-04 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to cd47 and antigen-binding fragment thereof
JP7744992B2 (ja) 2021-01-08 2025-09-26 北京韓美薬品有限公司 Ｐｄ－ｌ１と特異的に結合する抗体及びその抗原結合フラグメント
EP4276111A4 (en) 2021-01-08 2025-04-30 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
EP4284428A1 (en) 2021-01-26 2023-12-06 VIR Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2022204514A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
CN117642176A (zh) 2021-04-14 2024-03-01 爱尔兰国立科克大学 Psg1用于治疗骨关节炎
AU2022259536A1 (en) 2021-04-14 2023-11-09 University College Cork - National University Of Ireland, Cork Treatment of cerebrovascular events and neurological disorders
US20250101112A1 (en) 2021-07-26 2025-03-27 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN117589996A (zh) 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途
CN117586388A (zh) 2022-08-09 2024-02-23 深圳智源生物医药有限公司 改进的β淀粉样蛋白寡聚体特异性结合抗体
AU2022482294A1 (en) 2022-10-14 2025-05-15 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) * 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222080A1 (en) * 1973-03-22 1974-10-18 Viejo Jacques Stabilisation of pepsin - by salt formation with a carboxy polymethylene
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
SU1022988A1 (ru) * 1979-09-28 1983-06-15 Всесоюзный кардиологический научный центр АМН СССР Стабилизированна урокиназа,обладающа тромболитической активностью,и способ ее получени

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) * 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
JPS61155333A (ja) * 1984-11-30 1986-07-15 ビーチャム・グループ・ピーエルシー 新規化合物、その製法及びそれを含む医薬組成物

Also Published As

Publication number Publication date
SE8206173L (sv) 1983-05-01
FR2515684A1 (fr) 1983-05-06
DE3240174C2 (enExample) 1990-08-23
SE457800B (sv) 1989-01-30
US4495285B1 (enExample) 1986-09-23
DE3240174A1 (de) 1983-05-19
GB2110219B (en) 1985-01-09
GB2110219A (en) 1983-06-15
JPH0525470B2 (enExample) 1993-04-13
BR8206347A (pt) 1983-09-27
FR2515684B1 (fr) 1986-04-04
US4495285A (en) 1985-01-22
SE8206173D0 (sv) 1982-10-29
CH658669A5 (fr) 1986-11-28
CA1203764A (en) 1986-04-29

Similar Documents

Publication Publication Date Title
JPS5896026A (ja) 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) Plasminogen activator derivatives
Schlott et al. High yield production and purification of recombinant staphylokinase for thrombolytic therapy
JP2529816B2 (ja) 新規なヒト組織プラスミノゲン活性化因子突然変異体
JPH0378375B2 (enExample)
JPH05304957A (ja) 酵素誘導体、それらの製造法およびそれらを含有する医薬組成物
EP0217379B1 (en) Thrombolytic composition and a process for production thereof
JPS60252422A (ja) ハイブリツド蛋白質、その製法及びそれを含む医薬組成物
HU185223B (en) Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen
DK167738B1 (da) Fremgangsmaade til fremstilling af en oploesning med hoej specifik rumfangsaktivitet af et protein med vaevs-plasminogenaktivator(t-pa)-aktivitet, oploesning der indeholder protein med t-pa-aktivitet, og anvendelsen af oploesningen inden for human- og veterinaermedicinen
US4082612A (en) Plasminogen activator complex
CA1337796C (en) Plasminogen activator-heparin conjugates
JPH0567278B2 (enExample)
US4507283A (en) Pharmacologically active compounds
JPH07143878A (ja) 改善された繊維素溶解性及びトロンビン阻害作用を有する２官能性ウロキナーゼ変異体
JPS6360938A (ja) 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
CA1053661A (en) Protease-free proteins, and methods of manufacturing and using the same
JPH01240186A (ja) フィブリン特異性２本鎖プラスミノーゲンアクチベーター
JPH0195774A (ja) 修飾スーパーオキサイド・ジスムターゼ
RO116969B1 (ro) Derivati de stafilokinaza, procedeu pentru prepararea acestora si compozitie farmaceutica care ii contine
JPH0569508B2 (enExample)
JPS6140392B2 (enExample)
JPS59167520A (ja) 新規プラスミノ−ゲンアクチベ−タ誘導体およびその製造法ならびにそれを含有する医薬品
JPS60248621A (ja) 一本鎖組織プラスミノ−ゲンアクチベ−タ−の安定化方法
JPH0369332B2 (enExample)